Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Med Food ; 24(1): 28-32, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-32460589

RESUMO

Gymnema sylvestre, a plant typical of India, has long been known for its hypoglycemic effects. The objective of this study was to evaluate the effect of G. sylvestre administration on glycemic control, insulin secretion, and insulin sensitivity in patients with impaired glucose tolerance (IGT). A randomized, double-blind, placebo-controlled clinical trial was conducted in 30 patients with IGT. Fifteen patients randomly received G. sylvestre in doses of 300 mg b.i.d. and the other 15 received placebo in the same way. Before and after the intervention, anthropometric and metabolic measurements were taken, including 2-h oral glucose tolerance test (2-h OGTT), fasting plasma glucose, glycated hemoglobin A1c (A1C), and the lipid profile panel. Areas under the curve of glucose and insulin were calculated, as well as the insulinogenic, Stumvoll, and Matsuda indices. Wilcoxon, Mann-Whitney U, and chi-square or Fisher's exact tests were performed, and a P-value ≤.05 was considered statistically significant. There was a significant reduction in 2-h OGTT (9.1 ± 1.2 vs. 7.8 ± 1.7 mmol/L, P = .003), A1C (5.8 ± 0.3% vs. 5.4 ± 0.4%, P = .025), body weight, body mass index, and low-density lipoprotein cholesterol levels in the G. sylvestre group, with an increment in the Matsuda index (1.8 ± 0.8 vs. 2.4 ± 1.2, P = .008). At the end of the intervention, 46.7% of the patients obtained normal values in A1C. In conclusion, G. sylvestre administration in patients with IGT decreased 2-h OGTT and A1C, increasing insulin sensitivity. There were also improvements in anthropometric measures and the lipid profile.


Assuntos
Intolerância à Glucose , Gymnema sylvestre/química , Resistência à Insulina , Secreção de Insulina , Preparações de Plantas/uso terapêutico , Glicemia , Método Duplo-Cego , Intolerância à Glucose/tratamento farmacológico , Controle Glicêmico , Humanos , Índia , Insulina/metabolismo , Fitoterapia
2.
Rev. neurol. (Ed. impr.) ; 60(1): 30-34, 1 ene., 2015. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-131521

RESUMO

Introducción. Existen pocas evidencias notificadas de casos de epilepsia del lóbulo temporal asociadas a cisticercosis activa en su fase quística. El objetivo es presentar la correlación entre cisticercosis activa en zonas topográficas asociadas a epilepsia del lóbulo temporal, con las manifestaciones neuropsiquiátricas y el patrón de crisis parciales secundariamente generalizadas. Casos clínicos. Dos casos de pacientes adultos con manifestaciones neuropsiquiátricas de un año de evolución, refractarios a tratamiento farmacológico antipsicótico, y en quienes posteriormente aparecen crisis convulsivas parciales secundariamente generalizadas de inicio tardío. Se identifica la presencia de cisticercosis activa en el lóbulo temporal en un paciente, y en la ínsula, en el otro. Buen control clínico posterior al tratamiento con albendazol, pero se mantiene el mismo tratamiento anticonvulsionante para considerar la pertinencia de su retirada farmacológica. Conclusiones. La neurocisticercosis activa puede ser causa de trastornos neuropsiquiátricos adquiridos y de epilepsia del lóbulo temporal de inicio tardío cuando su topografía se encuentra en el circuito mesolímbico. El diagnóstico etiológico oportuno y el tratamiento apropiado permiten el control adecuado de su sintomatología y, potencialmente, su curación definitiva (AU)


Introduction. There are limited evidences reported of temporal lobe epilepsy associated with active cysticercosis in cystic stage. The objective is to present the correlation between active cysticercosis in topographical zones associated with temporal lobe epilepsy, with neuropsychiatric manifestations and pattern of secondarily generalized partial seizures. Case reports. Two cases of adult patients with neuropsychiatric manifestations of one year evolution, refractory to antipsychotic drug treatment, and who subsequently appear late onset partial-secondarily generalized seizures. Cysticercosis active presence in the temporal lobe in one patient, and the insula in the other, is identified. A better clinical control after albendazol treatment and subsequently anticonvulsant therapy only remained to evaluate pertinence of pharmacological withdrawal criteria. Conclusions. Active neurocysticercosis, may be the cause of acquired neuropsychiatric disorders and temporal lobe epilepsy of late onset when the topography is in the mesolimbic circuit. Early etiologic diagnosis and appropriate treatment allows adequate control of their symptoms and potentially final cure (AU)


Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Epilepsia do Lobo Temporal/complicações , Epilepsia do Lobo Temporal/diagnóstico , Epilepsia do Lobo Temporal/cirurgia , Neurocisticercose/diagnóstico , Neurocisticercose/tratamento farmacológico , Anticonvulsivantes/uso terapêutico , Albendazol/uso terapêutico , Epilepsia do Lobo Temporal/fisiopatologia , Epilepsia do Lobo Temporal , Neurocisticercose/complicações , Neurocisticercose , Imageamento por Ressonância Magnética/métodos
3.
Rev Neurol ; 60(1): 30-4, 2015 Jan 01.
Artigo em Espanhol | MEDLINE | ID: mdl-25522861

RESUMO

INTRODUCTION: There are limited evidences reported of temporal lobe epilepsy associated with active cysticercosis in cystic stage. The objective is to present the correlation between active cysticercosis in topographical zones associated with temporal lobe epilepsy, with neuropsychiatric manifestations and pattern of secondarily generalized partial seizures. CASE REPORTS: Two cases of adult patients with neuropsychiatric manifestations of one year evolution, refractory to antipsychotic drug treatment, and who subsequently appear late onset partial-secondarily generalized seizures. Cysticercosis active presence in the temporal lobe in one patient, and the insula in the other, is identified. A better clinical control after albendazol treatment and subsequently anticonvulsant therapy only remained to evaluate pertinence of pharmacological withdrawal criteria. CONCLUSIONS: Active neurocysticercosis, may be the cause of acquired neuropsychiatric disorders and temporal lobe epilepsy of late onset when the topography is in the mesolimbic circuit. Early etiologic diagnosis and appropriate treatment allows adequate control of their symptoms and potentially final cure.


TITLE: Epilepsia del lobulo temporal y neurocisticercosis activa: dos casos representativos.Introduccion. Existen pocas evidencias notificadas de casos de epilepsia del lobulo temporal asociadas a cisticercosis activa en su fase quistica. El objetivo es presentar la correlacion entre cisticercosis activa en zonas topograficas asociadas a epilepsia del lobulo temporal, con las manifestaciones neuropsiquiatricas y el patron de crisis parciales secundariamente generalizadas. Casos clinicos. Dos casos de pacientes adultos con manifestaciones neuropsiquiatricas de un año de evolucion, refractarios a tratamiento farmacologico antipsicotico, y en quienes posteriormente aparecen crisis convulsivas parciales secundariamente generalizadas de inicio tardio. Se identifica la presencia de cisticercosis activa en el lobulo temporal en un paciente, y en la insula, en el otro. Buen control clinico posterior al tratamiento con albendazol, pero se mantiene el mismo tratamiento anticonvulsionante para considerar la pertinencia de su retirada farmacologica. Conclusiones. La neurocisticercosis activa puede ser causa de trastornos neuropsiquiatricos adquiridos y de epilepsia del lobulo temporal de inicio tardio cuando su topografia se encuentra en el circuito mesolimbico. El diagnostico etiologico oportuno y el tratamiento apropiado permiten el control adecuado de su sintomatologia y, potencialmente, su curacion definitiva.


Assuntos
Anomia/etiologia , Epilepsia do Lobo Temporal/etiologia , Neurocisticercose/complicações , Transtorno de Pânico/etiologia , Albendazol/uso terapêutico , Anomia/tratamento farmacológico , Anti-Helmínticos/uso terapêutico , Anticonvulsivantes/uso terapêutico , Antipsicóticos/uso terapêutico , Carbamazepina/análogos & derivados , Carbamazepina/uso terapêutico , Citalopram/uso terapêutico , Diagnóstico Tardio , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/etiologia , Resistência a Medicamentos , Quimioterapia Combinada , Epilepsia do Lobo Temporal/tratamento farmacológico , Cefaleia/etiologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Pessoa de Meia-Idade , Neurocisticercose/diagnóstico , Neurocisticercose/tratamento farmacológico , Neurocisticercose/psicologia , Oxcarbazepina , Transtorno de Pânico/tratamento farmacológico , Perfenazina/uso terapêutico , Prednisona/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...